MedKoo Cat#: 565654 | Name: PF-06873600 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ebvaciclib, also known as PF-06873600, is an orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with potential antineoplastic activity. Upon administration, PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells.

Chemical Structure

PF-06873600 HCl
PF-06873600 HCl
CAS#PF-06873600 HCl

Theoretical Analysis

MedKoo Cat#: 565654

Name: PF-06873600 HCl

CAS#: PF-06873600 HCl

Chemical Formula: C20H28ClF2N5O4S

Exact Mass: 0.0000

Molecular Weight: 507.98

Elemental Analysis: C, 47.29; H, 5.56; Cl, 6.98; F, 7.48; N, 13.79; O, 12.60; S, 6.31

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
PF-06873600 HCl 2185857-97-8 (free base) 2185859-59-8 (SS-isomer)
Synonym
Ebvaciclib HCl; PF-06873600; PF 06873600; PF06873600; PF-06873600 HCl; PF-06873600 hydrochloride
IUPAC/Chemical Name
6-(Difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride
InChi Key
YAOJIKPNADLGIS-FOWJKZASSA-N
InChi Code
InChI=1S/C20H27F2N5O4S.ClH/c1-20(29)7-3-4-15(20)27-17-12(10-14(16(21)22)18(27)28)11-23-19(25-17)24-13-5-8-26(9-6-13)32(2,30)31;/h10-11,13,15-16,29H,3-9H2,1-2H3,(H,23,24,25);1H/t15-,20-;/m1./s1
SMILES Code
O=C1C(C(F)F)=CC2=CN=C(NC3CCN(S(=O)(C)=O)CC3)N=C2N1[C@H]4[C@](C)(O)CCC4.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 507.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1. Arora M, Moser J, Hoffman TE, Watts LP, Min M, Musteanu M, Rong Y, Ill CR, Nangia V, Schneider J, Sanclemente M, Lapek J, Nguyen L, Niessen S, Dann S, VanArsdale T, Barbacid M, Miller N, Spencer SL. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. Cell. 2023 Jun 8;186(12):2628-2643.e21. doi: 10.1016/j.cell.2023.05.013. Epub 2023 Jun 1. PMID: 37267950. 2: Freeman-Cook K, Hoffman RL, Miller N, Almaden J, Chionis J, Zhang Q, Eisele K, Liu C, Zhang C, Huser N, Nguyen L, Costa-Jones C, Niessen S, Carelli J, Lapek J, Weinrich SL, Wei P, McMillan E, Wilson E, Wang TS, McTigue M, Ferre RA, He YA, Ninkovic S, Behenna D, Tran KT, Sutton S, Nagata A, Ornelas MA, Kephart SE, Zehnder LR, Murray B, Xu M, Solowiej JE, Visswanathan R, Boras B, Looper D, Lee N, Bienkowska JR, Zhu Z, Kan Z, Ding Y, Mu XJ, Oderup C, Salek-Ardakani S, White MA, VanArsdale T, Dann SG. Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. Cancer Cell. 2021 Oct 11;39(10):1404-1421.e11. doi: 10.1016/j.ccell.2021.08.009. Epub 2021 Sep 13. PMID: 34520734. 3: Jeselsohn R, Schiff R, Grinshpun A. Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2. Cancer Cell. 2021 Oct 11;39(10):1302-1305. doi: 10.1016/j.ccell.2021.08.007. Epub 2021 Sep 9. PMID: 34506738. 4: Freeman-Cook KD, Hoffman RL, Behenna DC, Boras B, Carelli J, Diehl W, Ferre RA, He YA, Hui A, Huang B, Huser N, Jones R, Kephart SE, Lapek J, McTigue M, Miller N, Murray BW, Nagata A, Nguyen L, Niessen S, Ninkovic S, O'Doherty I, Ornelas MA, Solowiej J, Sutton SC, Tran K, Tseng E, Visswanathan R, Xu M, Zehnder L, Zhang Q, Zhang C, Dann S. Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer. J Med Chem. 2021 Jul 8;64(13):9056-9077. doi: 10.1021/acs.jmedchem.1c00159. Epub 2021 Jun 10. PMID: 34110834.
Wang L, Jin H, Jochems F, Wang S, Lieftink C, Martinez IM, De Conti G, Edwards F, de Oliveira RL, Schepers A, Zhou Y, Zheng J, Wu W, Zheng X, Yuan S, Ling J, Jastrzebski K, Santos Dias MD, Song JY, Celie PNH, Yagita H, Yao M, Zhou W, Beijersbergen RL, Qin W, Bernards R. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis. Nat Cancer. 2022 Nov;3(11):1284-1299. doi: 10.1038/s43018-022-00462-2. Epub 2022 Nov 22. PMID: 36414711.